141 related articles for article (PubMed ID: 16630140)
61. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.
Wang W; Epler J; Salazar LG; Riddell SR
Cancer Res; 2006 Jul; 66(13):6826-33. PubMed ID: 16818660
[TBL] [Abstract][Full Text] [Related]
62. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
[TBL] [Abstract][Full Text] [Related]
63. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.
Passoni L; Scardino A; Bertazzoli C; Gallo B; Coluccia AM; Lemonnier FA; Kosmatopoulos K; Gambacorti-Passerini C
Blood; 2002 Mar; 99(6):2100-6. PubMed ID: 11877285
[TBL] [Abstract][Full Text] [Related]
64. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes.
Schag K; Schmidt SM; Müller MR; Weinschenk T; Appel S; Weck MM; Grünebach F; Stevanovic S; Rammensee HG; Brossart P
Clin Cancer Res; 2004 Jun; 10(11):3658-66. PubMed ID: 15173072
[TBL] [Abstract][Full Text] [Related]
65. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
[TBL] [Abstract][Full Text] [Related]
66. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
[TBL] [Abstract][Full Text] [Related]
67. Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric tumor cells in vitro.
Cai YG; Fang DC; Chen L; Tang XD; Chen T; Yu ST; Luo YH; Xiong Z; Wang DX; Yang SM
Tumour Biol; 2007; 28(4):238-46. PubMed ID: 17717429
[TBL] [Abstract][Full Text] [Related]
68. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
[TBL] [Abstract][Full Text] [Related]
69. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
70. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
71. Identification of a common HLA-A*0201-restricted epitope among SSX family members by mimicking altered peptide ligands strategy.
He Y; Mao L; Lin Z; Deng Y; Tang Y; Jiang M; Li W; Jia Z; Wang J; Ni B; Wu Y
Mol Immunol; 2008 May; 45(9):2455-64. PubMed ID: 18295890
[TBL] [Abstract][Full Text] [Related]
72. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
73. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
[TBL] [Abstract][Full Text] [Related]
74. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.
Tanaka Y; Amos KD; Joo HG; Eberlein TJ; Goedegebuure PS
Int J Cancer; 2001 Nov; 94(4):540-4. PubMed ID: 11745441
[TBL] [Abstract][Full Text] [Related]
75. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients.
Harada M; Ishihara Y; Itoh K; Yamanaka R
Oncol Rep; 2007 Mar; 17(3):629-36. PubMed ID: 17273744
[TBL] [Abstract][Full Text] [Related]
76. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
[TBL] [Abstract][Full Text] [Related]
77. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.
Street MD; Doan T; Herd KA; Tindle RW
Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516
[TBL] [Abstract][Full Text] [Related]
78. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
[TBL] [Abstract][Full Text] [Related]
79. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice.
Heukamp LC; van der Burg SH; Drijfhout JW; Melief CJ; Taylor-Papadimitriou J; Offringa R
Int J Cancer; 2001 Feb; 91(3):385-92. PubMed ID: 11169964
[TBL] [Abstract][Full Text] [Related]
80. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.
Ochi T; Fujiwara H; Suemori K; Azuma T; Yakushijin Y; Hato T; Kuzushima K; Yasukawa M
Blood; 2009 Jan; 113(1):66-74. PubMed ID: 18820130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
